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Optimal management of central nervous system (CNS) infiltration is a key remaining challenge in delivering precision therapy for childhood acute lymphoblastic leukaemia (ALL) 1 . Most CNS relapses occur in children without high-risk features and minimal residual disease does not reliably predict CNS relapse. 1, 2 Consequently, all children receive intensive CNS-directed therapy, which is potentially toxic to the developing brain 3 . The nature of cells infiltrating the CNS is a subject of much debate with some believing that a subset of cells selectively traffic to the CNS compartment whilst others believe that all ALL cells are capable of entering the CNS. The majority of mechanistic work addressing this question has been performed in patient-derived xenograft (PDX) models. Here, we report the first description of the clonal architecture of CNS and paired bone marrow (BM) compartments in patients with ALL, using high throughput sequencing (HTS) of primary patient BM and cerebrospinal fluid (CSF) samples taken at diagnosis and relapse. This addresses a significant gap in our understanding of how faithfully PDX models recapitulate clonal architecture in patients. Our data support our hypothesis that CNS and BM ALL share common characteristics and after their development in the BM almost all B-cell precursor ALL clones are capable of disseminating to the CNS. In addition, they suggest that in most cases CNS and accompanying BM relapses are not intrinsically different biologically, often arising from the same subclones at the two sites.
Tailored CNS-directed therapy requires improved understanding of mechanisms of CNS relapse and development of more sensitive assays to track CNS response during therapy.
CNS leukaemia is usually detected by CSF cytology. CSF flow cytometry or PCR are more sensitive 1, 4, 5 , but increased detection at diagnosis has not improved prediction of CNS relapse, possibly because it measures disease load at baseline rather than response to therapy 6 . PDX models suggest that up to 80% of diagnostic BM samples can engraft in the CNS 7 and cellular bar-coding experiments show the clonal composition within murine CNS and BM compartments are similar 7 . This suggests the ability to enter the CNS-compartment is a generic property of ALL. However, these results contrast with other studies indicating that CNS leukaemic blasts may selectively express genes associated with trafficking. 2, 8, 9 Interpretation of PDX data has caveats, since CNS infiltration is measured without selective pressures of CNS-directed therapy or immunosurveillance and species differences may make microenvironments more or less permissive for expansion. The ultra-sensitivity of HTS detecting VDJ rearrangements comes with the problem of distinguishing leukaemia-specific from normal-background repertoire.
The frequency of most common IGH gene rearrangements from BM aspirates of healthy individuals has been shown to average 0.04 -0.08%. 14 For this study, a neoplastic clone was defined as rearrangements with frequencies >1% in an individual sample, or where the identical rearrangement (at level >1%) is seen in a paired sample at any level.
We analysed twelve consecutive patients with B-cell precursor ALL and CNS involvement.
High and low-risk patients were represented and four cases had a clinically isolated CNS Figure 1 and isolated CNS relapses in Figure 2 , detailed information on the identity and percentages of clones in different compartments is given in Supplementary table 2.
Firstly, we examined CNS and BM clones in the patient with overt CNS infiltration at original diagnosis (CNS004, Figure 1A ). The CNS and BM compartments share identical dominant clones albeit with reversed proportions between compartments. Next, we compared BM and CSF at the time of combined relapse, these results fell into two distinct patterns ( Figure 1G and Figure 1H ). In the majority, (5/7: CNS001, CNS003, CNS007, CNS008, CNS009) ( This mechanism is further supported by our data showing clones identified in the CNS at apparently isolated relapse are also detectable in the corresponding BM at low frequency.
Alternatively, relapse mechanisms are cell-intrinsic with certain subclones predetermined to be biologically fitter (presumably due to additional mutations), irrespective of their local microenvironment. In contrast, 2 of 11 patients with CNS relapse, had some separate clonal evolution between BM and CNS, although many shared clones were also seen. Figure 2) . The presence of the IGHV3-23/IGHD2-2*02/IGHJ6*03 clone in the diagnostic BM albeit at very low level also demonstrates there is V-V replacement at diagnosis. (B) CNS010. Dominant clone in diagnostic BM is IGHV3-15*01/IGHD6-19*01/IGHJ6*02 at 31%, there are three other subclones, 24% IGHV4-59*01/IGHD3-10*01/IGHJH3*02, 12% IGHV3-33*01/IGHD6-6*01/IGHJ2*01 and 6% IGHV1-46*01/IGHJ4*02. At time of CNS relapse the dominant clone is also IGHV3-15*01/IGHD6-19*01/IGHJ6*02 at 41%, however, the other three dominant clones present in diagnostic BM are undetectable in the CSF sample. The other dominant clone in the CNS relapse is IGHV4-59*01/ IGHD3-10*01/IGHJH3*02 at 46% which is only present at a level 0.0001% in diagnostic BM. The BM in morphological remission at time of CNS relapse shows very low level of the CNS dominant clone IGHV4-34*01/ IGHJ2*01 at a level 0.12% and the original diagnostic BM clone IGHV3-15*01/IGHD6-19*01/IGHJ6*02 0.05%. (C) CNS011. Dominant clones in CSF at CNS relapse IGHV4-34/IGHD3-9*01/IGHJ6*02 at 54% and IGHV3-33*01/IGHD3-10*02/IGHJ3*02 at 34%. These clones are detected at low level in BM at time of CNS relapse 0.54% and 0.33% respectively, with no additional dominant clones detected. (D) CNS012. Dominant clones in diagnostic BM are IGHV1-2*04/IGHD7-27*01/IGHJ2*01 and IGHV7-4-1*02/IGHD5-12*01/IGHJ6*02 at 32.4% and 31.7% respectively. In the CNS relapse CSF sample, the same two dominant clones are present at comparable levels. The BM at time of CNS relapse was morphologically negative, however, there was low-level positivity for both clones by both real-time PCR and HTS.
